Universidad Peruana Cayetano Heredia

Optimizing outcomes in multiple sclerosis: Consensus guidelines for the diagnosis and treatment of multiple sclerosis in Latin America

Mostrar el registro sencillo del ítem

dc.contributor.author Carra, A.
dc.contributor.author Macías Islas, M.A.
dc.contributor.author Gabbai, A.A.
dc.contributor.author Correale, J.
dc.contributor.author Bolana, C.
dc.contributor.author Sotelo, E.D.
dc.contributor.author Bonitto, J.G.
dc.contributor.author Vergara Edwards, F.
dc.contributor.author Vizcarra-Escobar, Darwin
dc.date.accessioned 2022-01-18T19:34:35Z
dc.date.available 2022-01-18T19:34:35Z
dc.date.issued 2011
dc.identifier.uri https://hdl.handle.net/20.500.12866/11027
dc.description.abstract Objective: The prevalence of multiple sclerosis (MS) in Latin America varies across different studies but an intermediate risk and increased frequency of the disease have been reported in recent years. The circumstances of Latin American countries are different from those of Europe and North America, both in terms of differential diagnoses and disease management. Methods: An online survey on MS was sent to 855 neurologists in nine Latin American countries. A panel of nine experts in MS analyzed the results. Results: Diagnostic and therapeutic recommendations were outlined with special emphasis on the specific needs and circumstances of Latin America. The experts proposed guidelines for MS diagnosis, treatment, and follow up, highlighting the importance of considering endemic infectious diseases in the differential diagnoses of MS, the identification of patients at high risk of developing MS in order to maximize therapeutic opportunities, early treatment initiation, and cost-effective control of treatment efficacy, as well as global assessment of disability. Conclusions: The experts recommended that healthcare systems allocate a longer consultation time for patients with MS, which must be conducted by neurologists trained in the management of the disease. All drugs currently approved must be available in all Latin American countries and must be covered by healthcare plans. The expert panel supported the creation of a permanent forum to discuss future clinical and therapeutic recommendations that may be useful in Latin American countries. en_US
dc.language.iso eng
dc.publisher SAGE Publications
dc.relation.ispartofseries Therapeutic Advances in Neurological Disorders
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Nuclear magnetic resonance imaging en_US
dc.subject health care system en_US
dc.subject South and Central America en_US
dc.subject azathioprine en_US
dc.subject cyclophosphamide en_US
dc.subject drug megadose en_US
dc.subject rituximab en_US
dc.subject systemic lupus erythematosus en_US
dc.subject health survey en_US
dc.subject follow up en_US
dc.subject Human T cell leukemia virus 1 en_US
dc.subject vasculitis en_US
dc.subject tuberculosis en_US
dc.subject differential diagnosis en_US
dc.subject treatment outcome en_US
dc.subject malnutrition en_US
dc.subject brucellosis en_US
dc.subject cyanocobalamin deficiency en_US
dc.subject cost effectiveness analysis en_US
dc.subject cysticercosis en_US
dc.subject alemtuzumab en_US
dc.subject Expanded Disability Status Scale en_US
dc.subject fingolimod en_US
dc.subject glatiramer en_US
dc.subject methylprednisolone en_US
dc.subject mitoxantrone en_US
dc.subject multiple sclerosis en_US
dc.subject natalizumab en_US
dc.subject practice guideline en_US
dc.subject health care en_US
dc.subject ocrelizumab en_US
dc.subject high risk patient en_US
dc.subject vascular disease en_US
dc.subject disability en_US
dc.subject virus infection en_US
dc.subject consultation en_US
dc.subject beta1a interferon en_US
dc.subject CADASIL en_US
dc.subject daclizumab en_US
dc.subject evoked visual response en_US
dc.subject glatiramer acetate en_US
dc.subject immunomodulators en_US
dc.subject interferon beta serine en_US
dc.subject interferon-beta en_US
dc.subject lacunar infarct en_US
dc.subject thrombophilia en_US
dc.title Optimizing outcomes in multiple sclerosis: Consensus guidelines for the diagnosis and treatment of multiple sclerosis in Latin America en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1177/1756285611423560
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.02.25
dc.relation.issn 1756-2864


Ficheros en el ítem

Ficheros Tamaño Formato Ver

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

info:eu-repo/semantics/restrictedAccess Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess

Buscar en el Repositorio


Listar

Panel de Control

Estadísticas